Related to Qiagen Acquires Intelligent Bio-Systems with Aim to Advance Next-Gen Sequencing

• Buyout Options Gaining a Foothold in Deals Means that More than the Price Is Right
  Buyout rights are attractive to smaller firms as they offer up-front payments and a longer-term path to liquidity.
  
• M&A Likely to Continue Growing Along with Deal Premiums and Multiples
  Slow comeback of IPO market will keep companies looking for opportunities to be acquired.
  
• Patient Privacy or Scientific Advances: Do They Have to Be Mutually Exclusive?
  Presidential Commission weighs pros and cons of making sequencing data available to researchers and patients.
  
• Why Biomarker Discovery Is Hard
  Differentiating which markers are in the driver’s seat and which are along for the ride is key.
  
• Are You Already Obsolete?
  To stay ahead in the ever-quickening world of research, scientists must be fast and cunning.
  
• Fearing Anchors Away After M&A
  San Diego, Maryland downplay prospect of clusters’ last stand.
  
• One Small Step, No Giant Leap for Privacy
  Privacy and Progress in Whole-Genome Sequencing report lacks implementation framework.
  
• The Long and the Short of DNA Sequencing
  Third-generation sequencers improve on second-generation systems by offering longer reads.
  
• Biggest Biotech Trends of 2012
  GEN takes a look back at some key biopharma developments of the past 12 months.
  
• 7 Biotech Trends for the Coming Year
  What does 2013 hold for the industry?
  
• Top 25 M&A Deals of 2012
  Who bought who last year? Find out here.
  
• 10 Predictions That Will Transform Healthcare
  Peer into GEN's crystal ball for a glimpse of what's to come.
  
• Arrivederci, GINA
  New rules on protecting genetic privacy are under way, as study rekindles debate over sharing vs. protecting data.
  
• Detecting Acquired Drug Resistance in Cancer
  New methods allow noninvasive analysis in blood plasma.
  
• Your Genes, Your Choice?
  Critics say the American College of Medical Genetics and Genomics’ recent recommendations for reporting incidental clinical sequencing results undermine patient autonomy.
  
• Metagenomics May Hold Key to Novel Antibiotic Discovery
  This relatively new science has the potential to fill a technological void.
  
• A Big Deal’s Winners and Losers
  The benefits, and costs, of Thermo Fisher’s $13.6B Life Tech purchase.
  
• Chips By Choice
  The technology that was slated to make microarrays obsolete has actually helped make them better.
  
• Human Genome Redux: Just a Numbers Game?
  Success of sequencing capabilities is dependent on tools to analyze the data.
  
• Moving Genomics Closer to the Clinic
  Foundation Medicine and Memorial Sloan-Kettering Cancer Center are working to translate genomic information into personalized cancer treatment.